Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on June 30, 2021, reporting events occurring on June 29, 2021. The filing pertains to corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Appointment: Corazon (Corsee) D. Sanders, Ph.D., was appointed as a Class II director effective June 29, 2021, serving until the 2024 annual meeting.
- Committee Assignment: Dr. Sanders was appointed to the Research and Development Committee.
- Board Composition: The Board size was fixed at nine directors, comprising three Class I, three Class II, and three Class III directors.
Guidance, Outlook, and Compensation
The filing contains no guidance, outlook, or management commentary regarding business operations or risks. Regarding compensation for the new appointment:
- Equity Grant: Dr. Sanders received 3,895 restricted stock units (RSUs).
- Stock Options: Dr. Sanders received an option to purchase up to 7,255 shares of common stock with an exercise price of $96.29 (the closing price on June 29, 2021).
- Indemnification: An indemnification agreement was executed, requiring the Company to indemnify Dr. Sanders to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 3,895 RSUs and 7,255 stock options granted.
- Review the Company's Non-Employee Director Compensation Policy to confirm the cash compensation component, which is not detailed in this filing.
- Confirm Dr. Sanders' independence status and any potential conflicts of interest given her board roles at Beigene, Molecular Templates, Legend Biotech, and AltruBio.
- Check subsequent filings for the impact of this appointment on the Research and Development Committee's strategic decisions.